Evicenter
Skyrizi (risankizumab-rzaa) in Plaque psoriasis
Manufacturer
AbbVie Inc.
Prescribing information
Skyrizi (opens in a new tab)
Questions
47
Last updated

All questions

Safety: Skyrizi (risankizumab-rzaa) in plaque psoriasis

4 questions · 2 sources

Side effects

What are the most common side effects of Skyrizi for plaque psoriasis?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: Table 4 columns are SKYRIZI (N=1306) and placebo (N=300), in that order, as n (%).

What are the long-term side effects of Skyrizi for psoriasis?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The approximately 9-year statement is from a pooled analysis of all explored doses that the safety page cites as a 2025 conference poster (Gordon et al.); the Prescribing Information reports controlled safety data through Week 52.

Do patients develop antibodies to Skyrizi (immunogenicity)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The pediatric qualification continues across a page break of the Prescribing Information.

Monitoring

Does Skyrizi require lab monitoring for psoriasis?

Note: The statements on TB evaluation and lab monitoring are from the safety page of the Skyrizi HCP site; the skyrizi-tuberculosis question covers TB evaluation. The liver test schedule in the Prescribing Information applies to Crohn’s disease and ulcerative colitis.